Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Mar 10, 2026
Reporting period
Not applicable
Filed with the SEC
Mar 12, 2026
CEOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001638643-26-000014
Filed / recorded
Mar 12, 2026, 8:24 PM UTC
Added to OQRO
Oct 2, 2026, 12:27 PM UTC
Parser
form4-xml-v1
Data quality
Verified: identifiers matched exactly
Issuer
GILEAD SCIENCES, INC.
Issuer CIK
882095
Ticker
GILD
Reporting person
Daniel Patrick O'day
Relationship
Director, Officer
Officer title
Chairman & CEO
Security
Restricted Stock Unit
Table
Derivative (Table II)
Transaction date
Mar 10, 2026
Transaction code
A
Shares / units
32,815
Acquired / disposed
Acquired (A)
Shares owned after
100,859
Ownership form
Direct
Amendment
No
Footnotes from the filing
Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.